Tandem Diabetes Care Announces Director Changes and Shareholder Votes

Ticker: TNDM · Form: 8-K · Filed: 2024-05-23T00:00:00.000Z

Sentiment: neutral

Topics: governance, board-changes, shareholder-vote

Related Tickers: TNDM

TL;DR

Tandem Diabetes Care swapped a director and is holding shareholder votes.

AI Summary

Tandem Diabetes Care, Inc. announced on May 22, 2024, the departure of director Dr. Steven R. Smith and the election of Dr. Jennifer L. Schneider as a new director. The company also reported on compensatory arrangements for certain officers and submitted matters to a vote of security holders.

Why It Matters

Changes in board composition can signal shifts in company strategy or governance, while shareholder votes directly impact corporate decision-making.

Risk Assessment

Risk Level: low — The filing reports routine corporate governance changes and shareholder matters, which typically carry low immediate risk.

Key Players & Entities

FAQ

Who has departed from Tandem Diabetes Care's board of directors?

Dr. Steven R. Smith has departed from the board of directors.

Who has been elected as a new director to Tandem Diabetes Care's board?

Dr. Jennifer L. Schneider has been elected as a new director.

What is the exact date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is May 22, 2024.

What are the main items covered in this Form 8-K filing?

The filing covers the departure of directors, election of directors, compensatory arrangements of certain officers, and submission of matters to a vote of security holders.

What is the principal executive office address for Tandem Diabetes Care, Inc.?

The principal executive offices are located at 12400 High Bluff Drive, San Diego, California 92130.

From the Filing

0001438133-24-000118.txt : 20240523 0001438133-24-000118.hdr.sgml : 20240523 20240523162747 ACCESSION NUMBER: 0001438133-24-000118 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240522 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240523 DATE AS OF CHANGE: 20240523 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TANDEM DIABETES CARE INC CENTRAL INDEX KEY: 0001438133 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 204327508 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36189 FILM NUMBER: 24978702 BUSINESS ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 BUSINESS PHONE: 858-366-6900 MAIL ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 8-K 1 tndm-20240522.htm 8-K tndm-20240522 0001438133 FALSE 0001438133 2024-05-22 2024-05-22   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 8-K ____________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 ____________________________ Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) ____________________________ Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer  Identification No.) 12400 High Bluff Drive 92130 San Diego California (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 858 )  366-6900 N/A (Former name or former address, if changed since last report) ____________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share TNDM Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ____________________________ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On May 22, 2024, the stockholders of Tandem Diabetes Care, Inc. (the “Company”) approved the Company’s 2013 Employee Stock Purchase Plan, as amended, and the Company’s 2023 Long-Term Incentive Plan, as amended, as described in Item 5.07 be

View on Read The Filing